TY - JOUR
T1 - Heregulin in breast cancer
T2 - Old story, new paradigm
AU - Khurana, Ashwani
AU - Gonzalez-Guerrico, Anatilde
AU - Lupu, Ruth
PY - 2014
Y1 - 2014
N2 - Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
AB - Heregulin (HRG), a combinatorial ligand for the epidermal growth factor receptor family, is expressed in about 30% of breast cancer tumors. HRG induces tumorigenicity and metastasis of breast cancer cells and promotes hormone-independent growth [1]. Although HRG has been studied mostly in the context of the HRG receptor family, accumulating evidence suggests that HRG plays distinctive and causative roles in breast cancer tumorigenesis independent from the HRG receptors, demanding a comprehensive and independent study of HRG as a unique growth factor. This review provides a consolidated view of HRG and its biological role in the development, progression, and maintenance of breast cancer. Further, it provides further evidence that HRG is implicated in breast cancer resistance and targeting HRG may possibly be a beneficial tool to target a subgroup of breast carcinomas.
KW - Breast cancer
KW - Her3 receptor
KW - Heregulin
KW - Tumorigenicity
UR - http://www.scopus.com/inward/record.url?scp=84906214845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906214845&partnerID=8YFLogxK
U2 - 10.2174/1381612819666131125151519
DO - 10.2174/1381612819666131125151519
M3 - Review article
C2 - 24283953
AN - SCOPUS:84906214845
SN - 1381-6128
VL - 20
SP - 4874
EP - 4878
JO - Current pharmaceutical design
JF - Current pharmaceutical design
IS - 30
ER -